Evidence map›Paper›PMID 38661486›Full record

ArticleMovement disorders clinical practice2024

Salivary α-Synuclein as a Candidate Biomarker of Parkinsonism in 22q11.2 Deletion Syndrome.

Martina Fanella, Emanuele Cerulli Irelli, Tommaso Accinni, Fabio Di Fabio, Carolina Putotto, Federica Pulvirenti, Francesco E Bellomi, Carlo Di Bonaventura, Giorgio Vivacqua

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Unlocking Parkinson's disease: the role of microRNAs in regulation, diagnosis, and therapy.Apoptosis : an international journal on programmed cell death · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Martina FanellaFabrizio Spaziani Hospital, Frosinone, Italy.
Emanuele Cerulli IrelliDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Tommaso AccinniDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Fabio Di FabioDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Carolina PutottoDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Federica PulvirentiRegional Reference Centre for Primary Immune Deficiencies, AOU Policlinico Umberto I, Rome, Italy.
Francesco E BellomiDepartment of Microscopic and Ultrastructural Anatomy - Integrated Research Center (PRAAB) - Campus Biomedico University of Rome, Rome, Italy.
Carlo Di BonaventuraDepartment of Human Neurosciences, Sapienza University, Rome, Italy.ORCID 0000-0003-1890-5409
Giorgio VivacquaDepartment of Microscopic and Ultrastructural Anatomy - Integrated Research Center (PRAAB) - Campus Biomedico University of Rome, Rome, Italy.
Policlinico Umberto I · ITSapienza University of Rome · ITUniversità Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background22q11.2 deletion syndrome (22q11.2DS) has been linked to an increased risk of early-onset Parkinson's disease. However, the pathophysiological mechanisms underlying parkinsonism remain poorly understood.

objectiveThe objective is to investigate salivary total α-synuclein levels in 22q11.2DS patients with and without parkinsonian motor signs.

methodsThis cross-sectional study included 10 patients with 22q11.2DS with parkinsonism (Park+), ten 22q11.2DS patients without parkinsonism (Park-), and 10 age and sex-comparable healthy subjects (HS). Salivary and serum α-synuclein levels were measured using enzyme-linked immunosorbent assay.

resultsSalivary total α-synuclein concentration was significantly lower in Park (+) patients than in Park (-) patients and HS (P = 0.007). In addition, salivary α-synuclein showed good accuracy in discriminating Park (+) from Park (-) patients (area under the curve = 0.86) and correlated with motor severity and cognitive impairment.

conclusionThis exploratory study suggests that the parkinsonian phenotype of 22q11.2DS is associated with a reduced concentration of monomeric α-synuclein in biological fluids.

Indexed as

alpha-SynucleinBiomarkersDiGeorge SyndromeParkinsonian DisordersSalivaAdolescentAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedYoung Adultalpha-SynucleinBiomarkersDiGeorge syndromeParkinson's disease (PD)serumα synuclein (a‐synuclein)

Identifiers

PMID38661486
PMCPMC11233847
OpenAlexW4395465379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.